









Markets
/
Stocks
/
nasdaq-cron
/

Cronos Group Inc

CRON

2.670USD

+0.090+3.49%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.02BMarket Cap

55.43P/E TTM



Cronos Group Inc

2.670

+0.090+3.49%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

59 / 175

Overall Ranking

175 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Hold

Current Rating

2.900

Target Price

+11.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Cronos Group Inc. is a Canada-based global cannabinoid company engaged in building intellectual property by advancing cannabis research, technology and product development. The Company operates through one segment, which is comprised of operations in Canada and Israel and is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s international brand portfolio includes Spinach, PEACE NATURALS, and Lord Jones. The Spinach brand offers pre-rolls infused with cold-filtered cannabis extract and coated in kief, and all-in-one disposable vapes. The Lord Jones is a hemp-derived cannabidiol (CBD) brand. Its Lord Jones Hash Fusions are a line-up of premium ice water hash infused pre-rolls. This brand also offers vapes and edibles. Its PEACE NATURALS offer Peppermint CBD, a blend of CBD extract, quality medium-chain triglycerides (MCT) oil, and a hint of natural peppermint flavor.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 35.58% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 41.08M.%!(EXTRA int=2)

Overvalued

The company’s latest PE is 52.77, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 238.43M shares, decreasing 2.03% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.16.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 8.40, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 33.45M, representing a year-over-year increase of 20.51%, while its net profit experienced a year-over-year increase of 353.48%.

Score

Industry at a Glance

Previous score

8.71

Change

-0.31



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.17

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.38

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 4.18, which is higher than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 52.77, which is -108.31% below the recent high of -4.38 and 120.30% above the recent low of -10.71.

Score

Industry at a Glance

Previous score

4.18

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 59/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 6.00, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Cronos Group Inc is 2.90, with a high of 2.90 and a low of 2.90.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Hold

Current Rating

2.900

Target Price

+12.40%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Cronos Group Inc

CRON

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 7.28, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 2.73 and the support level at 2.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.65

Change

-1.37

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.011

Neutral

RSI(14)

63.949

Neutral

STOCH(KDJ)(9,3,3)

70.608

Buy

ATR(14)

0.097

Low Volatility

CCI(14)

182.013

Buy

Williams %R

16.000

Overbought

TRIX(12,20)

0.341

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.584

Buy

MA10

2.556

Buy

MA20

2.557

Buy

MA50

2.337

Buy

MA100

2.150

Buy

MA200

2.031

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Altria Group Inc

156.57M

Gorenstein (Michael Ryan)

12.51M

+22.65%

Adler (Jason Marc)

9.88M

+0.61%

Chescapmanager, L.L.C.

7.95M

Quinn Opportunity Partners LLC

4.30M

+2109.62%

Tidal Investments LLC

5.37M

+9.94%

Gotham Green Partners, LLC

4.52M

Cannell Capital, LLC

6.33M

+284.83%

Dimensional Fund Advisors, L.P.

2.79M

+1.40%

Global X Investments Canada Inc.

2.19M

-0.37%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 5.31, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.63. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.